January 2013

Researchers have identified a potential predictive marker for survival in cases of mCRC treated with bevacizumab (Avastin), suggesting that patients who have the appropriate biomarker could experience a greater benefit when given the drug.

An analysis of the phase III AFFIRM trial showed that enzalutamide significantly delayed the time to first skeletal-related event and significantly improved pain and quality of life compared with placebo in men with mCRPC who had received prior docetaxel.